Michele Maio

Michele Maio

UNVERIFIED PROFILE

Are you Michele Maio?   Register this Author

Register author
Michele Maio

Michele Maio

Publications by authors named "Michele Maio"

Are you Michele Maio?   Register this Author

100Publications

14273Reads

35Profile Views

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2019 10 28;381(16):1535-1546. Epub 2019 Sep 28.

From the Royal Marsden NHS Foundation Trust, London (J.L.), and the College of Medicine, Swansea University, Swansea (J.W.) - both in the United Kingdom; the Oncology Institute of Veneto IRCCS, Padua (V.C.-S.), the European Institute of Oncology, IRCCS, Milan (P.F.F.), Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples (P.A.A.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and the Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital, Siena (M.M.) - all in Italy; the University of Colorado Cancer Center, Aurora (R.G.); Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille Hôpital Timone, Marseille (J.-J.G.), and Université de Paris, INSERM Unité 976, Assistance Publique-Hôpitaux de Paris Dermatology and Centres d'Investigation Clinique, Saint Louis Hospital, Paris (C.L.) - both in France; the Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); the University of Michigan, Ann Arbor (C.D.L.); Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Universitäts Spital, Zurich, Switzerland (R.D.); Cross Cancer Institute, Edmonton, AB (M.S.), and the Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Tasman Oncology Research, Southport, QLD (A.H.), the Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney, Sydney, NSW (M.S.C., G.V.L.), and the Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and the Peter MacCallum Cancer Centre, Melbourne, VIC (G.M.) - all in Australia; General University Hospital Gregorio Marañon and Centro de Investigación Biomédica en Red de Oncología, Madrid (I.M.-R.); the Netherlands Cancer Institute, Amsterdam (J.H.); the Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Leuven, Leuven, Belgium (P.S.); University of California San Diego Health-La Jolla Moores Cancer Center, La Jolla (G.A.D.); the Department of Oncology, Odense University Hospital, Odense, Denmark (L.B.); Bristol-Myers Squibb, Princeton, NJ (J.I.R., A.B., A.M.); Dana-Farber Cancer Institute, Boston (F.S.H.); and the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1910836DOI Listing
October 2019

Immunotherapy of brain metastases: breaking a "dogma".

J Exp Clin Cancer Res 2019 Oct 17;38(1):419. Epub 2019 Oct 17.

Department of Oncology, Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital of Siena, Viale Bracci, 14, 53100, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1426-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798349PMC
October 2019

The future of mesothelioma treatment: time to shift gear.

Lancet Respir Med 2019 Jul 15;7(7):554-555. Epub 2019 May 15.

Department of Oncology, Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Siena 53100, Italy.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22132600193017
Publisher Site
http://dx.doi.org/10.1016/S2213-2600(19)30171-7DOI Listing
July 2019

The Effects of Conflict on Fertility: Evidence From the Genocide in Rwanda.

Demography 2019 06;56(3):935-968

University of Naples Federico II, Naples, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13524-019-00780-8
Publisher Site
http://dx.doi.org/10.1007/s13524-019-00780-8DOI Listing
June 2019

The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology.

Cancer Immunol Immunother 2019 Jan 18;68(1):143-150. Epub 2018 Dec 18.

Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Viale Mario Bracci, 16, 53100, Siena, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-018-2286-x
Publisher Site
http://dx.doi.org/10.1007/s00262-018-2286-xDOI Listing
January 2019

Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge.

Cancer Immunol Immunother 2018 08 26;67(8):1317-1324. Epub 2018 Jun 26.

Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Viale Mario Bracci n. 16, 53100, Siena, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-018-2191-3
Publisher Site
http://dx.doi.org/10.1007/s00262-018-2191-3DOI Listing
August 2018

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.

Lancet Respir Med 2018 06 15;6(6):451-460. Epub 2018 May 15.

Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22132600183015
Publisher Site
http://dx.doi.org/10.1016/S2213-2600(18)30151-6DOI Listing
June 2018

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

N Engl J Med 2018 May 15;378(19):1789-1801. Epub 2018 Apr 15.

From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille (J.-J.G.) - all in France; Netherlands Cancer Institute-Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical Center Nijmegen, Nijmegen (R.K.) - all in the Netherlands; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo (M. Mandala), Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione G. Pascale, Naples (P.A.A.), and Universita Degli Studi Di Siena-Policlinico le Scotte, Siena (M. Maio) - all in Italy; Melanoma Institute Australia, the University of Sydney, and Mater and Royal North Shore Hospitals (G.V.L.) and Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney (M.S.C.), Sydney, Princess Alexandra Hospital, University of Queensland, Brisbane (V.A.), Alfred Hospital (A.H.) and Peter MacCallum Cancer Centre (S. Sandhu), Melbourne, VIC, and Fiona Stanley Hospital-University of Western Australia-Edith Cowan University Perth, Perth (A.K.) - all in Australia; Cancer Research Center, Moscow (M.L.); Royal Marsden Hospital, London (J.L.); Hospital Clinic Universitari de Barcelona, Barcelona (S.P.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); University Hospital Essen, Essen and German Cancer Consortium, Heidelberg (D.S.), and the Skin Cancer Center, Department of Dermatology, Hannover Medical School, Hannover (R.G.) - all in Germany; Washington University School of Medicine, St. Louis (L.H.-A.); Centre Hospitalier de l'Université de Montréal (CHUM), Centre de Recherche du CHUM, Montreal (R.J.); Christie NHS Foundation Trust, Manchester, United Kingdom (P.L.); Merck, Kenilworth, NJ (N.I.); and the European Organization for the Research and Treatment of Cancer Headquarters, Brussels (S.M., S. Suciu).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1802357DOI Listing
May 2018

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Authors:
Franck Pagès Bernhard Mlecnik Florence Marliot Gabriela Bindea Fang-Shu Ou Carlo Bifulco Alessandro Lugli Inti Zlobec Tilman T Rau Martin D Berger Iris D Nagtegaal Elisa Vink-Börger Arndt Hartmann Carol Geppert Julie Kolwelter Susanne Merkel Robert Grützmann Marc Van den Eynde Anne Jouret-Mourin Alex Kartheuser Daniel Léonard Christophe Remue Julia Y Wang Prashant Bavi Michael H A Roehrl Pamela S Ohashi Linh T Nguyen SeongJun Han Heather L MacGregor Sara Hafezi-Bakhtiari Bradly G Wouters Giuseppe V Masucci Emilia K Andersson Eva Zavadova Michal Vocka Jan Spacek Lubos Petruzelka Bohuslav Konopasek Pavel Dundr Helena Skalova Kristyna Nemejcova Gerardo Botti Fabiana Tatangelo Paolo Delrio Gennaro Ciliberto Michele Maio Luigi Laghi Fabio Grizzi Tessa Fredriksen Bénédicte Buttard Mihaela Angelova Angela Vasaturo Pauline Maby Sarah E Church Helen K Angell Lucie Lafontaine Daniela Bruni Carine El Sissy Nacilla Haicheur Amos Kirilovsky Anne Berger Christine Lagorce Jeffrey P Meyers Christopher Paustian Zipei Feng Carmen Ballesteros-Merino Jeroen Dijkstra Carlijn van de Water Shannon van Lent-van Vliet Nikki Knijn Ana-Maria Mușină Dragos-Viorel Scripcariu Boryana Popivanova Mingli Xu Tomonobu Fujita Shoichi Hazama Nobuaki Suzuki Hiroaki Nagano Kiyotaka Okuno Toshihiko Torigoe Noriyuki Sato Tomohisa Furuhata Ichiro Takemasa Kyogo Itoh Prabhu S Patel Hemangini H Vora Birva Shah Jayendrakumar B Patel Kruti N Rajvik Shashank J Pandya Shilin N Shukla Yili Wang Guanjun Zhang Yutaka Kawakami Francesco M Marincola Paolo A Ascierto Daniel J Sargent Bernard A Fox Jérôme Galon

Lancet 2018 05 10;391(10135):2128-2139. Epub 2018 May 10.

INSERM, Laboratory of Integrative Cancer Immunology, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Sorbonne Universités, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)30789-XDOI Listing
May 2018

New horizons from immunotherapy in malignant pleural mesothelioma.

J Thorac Dis 2018 Jan;10(Suppl 2):S322-S332

Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.

View Article

Download full-text PDF

Source
http://jtd.amegroups.com/article/view/18245/14610
Publisher Site
http://dx.doi.org/10.21037/jtd.2017.12.88DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830566PMC
January 2018

Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.

Endocrine 2017 Dec 12;58(3):535-541. Epub 2017 Apr 12.

Section of Endocrinology, Department of Medical, Surgical and Neurological sciences, University of Siena, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-017-1289-2DOI Listing
December 2017

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

N Engl J Med 2017 11 10;377(19):1824-1835. Epub 2017 Sep 10.

From New York University Perlmutter Cancer Center, New York (J.W.); Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M. Mandala), Medical Oncology, National Cancer Institute, Milan (M.D.V.), Oncology Institute of Veneto Istituti di Ricovero e Cura a Carattere Scientifico, Padua (V.C.-S.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M. Maio), Ospedale Policlinico San Martino, Genoa (P.Q.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; National and Kapodistrian University of Athens, Athens (H.J.G.); Hospital Clinic de Barcelona, Barcelona (A.M.A.), and General University Hospital Gregorio Marañón, Madrid (I.M.-R.) - both in Spain; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); Hospices Civils de Lyon, Pierre Bénite (S.D.), Aix-Marseille University, Hospital de la Timone, Marseille (J.-J.G.), Institut Universitaire du Cancer de Toulouse and Centre Hospitalier Universitaire (CHU), Toulouse (N.M.), Université Lille, INSERM Unité 1189, CHU Lille, Lille (L.M.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint Louis, Université Paris Diderot, Paris (C.L.) - all in France; Oncology Center Sf. Nectarie, Craiova, Romania (M. Schenker); Princess Margaret Cancer Centre, University of Toronto, Toronto (M.O.B.), and Cross Cancer Institute, Edmonton, AB (M. Smylie) - both in Canada; the Department of Oncology, University of Oxford, Oxford (M.R.M.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; Gallipoli Medical Research Foundation and University of Queensland, Queensland, VIC (V.A.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney (G.V.L.) - all in Australia; University of Colorado, Denver (R.G.); Winship Cancer Institute, Emory University School of Medicine, Atlanta (R.R.K.); Georgetown-Lombardi Comprehensive Cancer Center, Washington DC (M.B.A.); University of Washington, Seattle (S.B.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Nagoya University Graduate School of Medicine, Nagoya (K.Y.), and the National Cancer Center Hospital, Tokyo (N.Y.) - both in Japan; Seoul National University Hospital, Seoul, South Korea (T.M.K.); and Bristol-Myers Squibb, Princeton, NJ (V.P, J.S., A.Q.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709030DOI Listing
November 2017

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2017 10 11;377(14):1345-1356. Epub 2017 Sep 11.

From the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W., M.A.P., M.K.C.); Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua (V.C.-S.), European Institute of Oncology, Milan (P.F.F.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; University of Colorado, Denver (R.G.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Aix-Marseille University, Hôpital de la Timone, Marseille (J.-J.G.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint-Louis, Université Paris Diderot, Paris (C.L.) - both in France; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); University of Michigan, Ann Arbor (C.D.L.); the College of Medicine, Swansea University, Swansea (J.W.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Cross Cancer Institute, Edmonton, AB (M.S.), and Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Universitäts Spital, Zurich, Switzerland (R.D.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney (M.S.C.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and Peter MacCallum Cancer Centre (G.M.) and the Olivia Newton-John Cancer Research Institute, University of Melbourne (J.C.), Melbourne, VIC - all in Australia; Netherlands Cancer Institute, Amsterdam (J.H.); University Hospitals Leuven, KU Leuven, Leuven, Belgium (O.B.); General University Hospital Gregorio Marañón, Madrid (I.M.-R.); Northwestern University, Chicago (J.S.); Bristol-Myers Squibb, Princeton, NJ (D.W., L.R., R.B.); and the Dana-Farber Cancer Institute, Boston (F.S.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778PMC
October 2017

Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT).

Cytokine Growth Factor Rev 2017 08 16;36:1-3. Epub 2017 Jun 16.

Cellular Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCSS San Raffaele Scientific Institute, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cytogfr.2017.06.004DOI Listing
August 2017

Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.

Cytokine Growth Factor Rev 2017 08 12;36:25-31. Epub 2017 Jul 12.

Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cytogfr.2017.07.003DOI Listing
August 2017

Immunotherapy targeting immune check-point(s) in brain metastases.

Cytokine Growth Factor Rev 2017 08 13;36:33-38. Epub 2017 Jul 13.

Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cytogfr.2017.07.002DOI Listing
August 2017

ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies.

Methods Mol Biol 2016 ;1393:133-9

Medical Oncology and Immunotherapy, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-3338-9_13DOI Listing
December 2016

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

N Engl J Med 2016 11 7;375(19):1845-1855. Epub 2016 Oct 7.

From Gustave Roussy Cancer Campus Grand Paris, Villejuif (A.M.M.E., C.R.), Aix-Marseille University, Hôpital de La Timone, Marseille (J.-J.G.), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris (C.L.), University Lille, INSERM Unité-1189, Centre Hospitalier Universitaire (CHU) Lille, Service de Dermatologie, Lille (L.M.), and CHU Lyon, Lyon (L.T.) - all in France; the Oncology Institute of Veneto-Istituto di Ricovero e Cura a Carattere Scientifico, Padua (V.C.-S.), Istituto Nazionale Tumori Fondazione G. Pascale, Naples (P.A.A.), Istituti Fisioterapici Ospitalieri, Rome (V.F.), University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), and the European Institute of Oncology, Milan (A.T.) - all in Italy; University of Zurich Hospital, Zurich, Switzerland (R.D.); Memorial Sloan Kettering Cancer Center, New York (J.D.W.); Aarhus University Hospital, Aarhus (H.S.), and Odense University Hospital, Odense (L.B.) - both in Denmark; the Angeles Clinic and Research Institute, Los Angeles (O.H.); Oncology Specialists, Park Ridge, IL (J.M.R.); Cross Cancer Institute, Edmonton, AB, Canada (M.S.); H. Lee Moffitt Cancer Center, Tampa, FL (J.S.W.); Broomfield Hospital, Chelmsford, United Kingdom (S.T.); Universitätsklinikum Schleswig-Holstein, Kiel (A.H.), and University Hospital Heidelberg, Heidelberg (J.C.H.) - both in Germany; Dana-Farber Cancer Institute, Boston (F.S.H.); Bristol-Myers Squibb, Princeton, NJ (C.T., V.P.); and the European Organization for Research and Treatment of Cancer, Brussels (G.S., S.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648545PMC
November 2016

"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015.

Cancer Immunol Immunother 2016 11 12;65(11):1423-1431. Epub 2016 Sep 12.

Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, V.le Bracci, 16, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-016-1899-1DOI Listing
November 2016

Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.

Future Oncol 2015 ;11(9):1355-62

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.15.55DOI Listing
February 2016

"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014.

Cancer Immunol Immunother 2016 Jan 6;65(1):119-26. Epub 2015 May 6.

Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, V.le Bracci, 16, Siena, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-015-1699-z
Publisher Site
http://dx.doi.org/10.1007/s00262-015-1699-zDOI Listing
January 2016

Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy.

Clin Cancer Res 2015 Sep;21(18):4040-7

Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2914DOI Listing
September 2015

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

N Engl J Med 2015 Jul 31;373(1):23-34. Epub 2015 May 31.

From the Department of Medical Oncology, Royal Marsden Hospital, London (J.L.), and South West Wales Cancer Institute, Singleton Hospital, Swansea (J.W.) - both in the United Kingdom; Melanoma Oncology Unit, Veneto Region Oncology Research Institute, Padua (V.C.-S.), Oncology of Melanoma Unit, European Institute of Oncology, Milan (P.F.F.), University Hospital of Siena, Siena (M.M.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; Division of Medical Oncology, University of Colorado, Denver, Denver (R.G.); Aix-Marseille University, Hôpital de La Timone, Assitance Publique-Hôpitaux de Marseille, Marseille (J.J.G.), and Hôtel Dieu Place Alexis Ricordeau, Nantes (B.D.) - both in France; Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); Departments of Internal Medicine and Dermatology, University of Michigan, Ann Arbor (C.D.L.); Department of Dermatology, University of Essen, Essen, Germany (D.S.); University of Zürich Hospital, Zurich, Switzerland (R.D.); Cross Cancer Institute, Edmonton, AB, Canada (M. Smylie); Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland (P.R.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), and Westmead and Blacktown Hospitals (M.S.C.) and Melanoma Institute Australia (M.S.C., G.V.L.), University of Sydney, and the Mater Hospital (G.V.L.), Sydney, and Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC (G.A.M.) - all in Australia; Division of Medical Oncology, the Netherlands Cancer Institute, Amsterdam (J.B.H.); Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid (I.M.-R.); Ludwig Center, Memorial Sloan Kettering Cancer Center (M.K.C., M.A.P., J.D.W.) and Weill Cornell Medical College (M.K.C., M.A.P., J.D.W.) - both in New York; Huntsman Cancer Institute, University of Utah, Salt Lake City (K.G.); Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital, Yale University Sc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1504030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698905PMC
July 2015

Immunologic checkpoints for cancer treatment: a continuing success.

Semin Oncol 2015 Jun 12;42(3):362. Epub 2015 Feb 12.

Medical Oncology and Immunotherapy, Ospedale Santa Maria alle Scotte, Istituto Toscano Tumori, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2015.02.017DOI Listing
June 2015

The ipilimumab lesson in melanoma: achieving long-term survival.

Semin Oncol 2015 Jun 17;42(3):387-401. Epub 2015 Feb 17.

AP-HP, Hôpital Saint-Louis, Département de Dermatologie, Paris, France; INSERM U976, Paris 7 University, Paris, France; Université Paris-Diderot, Sorbonne Paris Cité, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2015.02.005DOI Listing
June 2015

Immune checkpoint blockade in malignant mesothelioma.

Semin Oncol 2015 Jun 24;42(3):418-22. Epub 2015 Feb 24.

Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2015.02.001DOI Listing
June 2015

Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.

Semin Oncol 2015 Jun 14;42(3):429-35. Epub 2015 Feb 14.

Gustave Roussy Cancer Campus Grand Paris and University Paris-Sud, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2015.02.010DOI Listing
June 2015

Epigenetics meets immune checkpoints.

Semin Oncol 2015 Jun 14;42(3):506-13. Epub 2015 Feb 14.

Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2015.02.003DOI Listing
June 2015

Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy.

Vaccines (Basel) 2015 May 21;3(2):420-8. Epub 2015 May 21.

Division of Medical Oncology and Immunotherapy, University Hospital of Siena, V. le Bracci, 16, Siena 53100, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/vaccines3020420DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494352PMC
May 2015

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

J Clin Oncol 2015 Apr 23;33(10):1191-6. Epub 2015 Feb 23.

Michele Maio, University Hospital of Siena, Siena; Vanna Chiarion-Sileni, Veneto Oncology Institute-Istituto Di Ricovero e Cura a Carattere Scientifico, Padova; Alessandro Testori, Istituto Europeo di Oncologia, Milan, Italy; Jean-Jacques Grob, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Timone, Marseille; Luc Thomas, Lyon 1 University, Centre Hospitalier Lyon Sud, Pierre Bénite; Caroline Robert, Institute Gustave Roussy, Villejuif, France; Steinar Aamdal, Oslo University Hospital and Radium Hospital, Oslo, Norway; Igor Bondarenko, Dnepropetrovsk State Medical Academy, Dnepropetrovsk, Ukraine; Claus Garbe, University Medical Center, Tübingen, Germany; Tai-Tsang Chen and Marina Tschaika, Bristol-Myers Squibb, Wallingford, CT; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.6018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795709PMC
April 2015

"Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013.

Cancer Immunol Immunother 2015 Jan 4;64(1):131-5. Epub 2014 Jul 4.

Division of Medical Oncology and Immunotherapy, Department of Oncology, Istituto Toscano Tumori, University Hospital of Siena, Viale Mario Bracci n. 16, 53100, Siena, Italy,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-014-1577-0DOI Listing
January 2015

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?

Cancer Immunol Immunother 2015 Jan 19;64(1):105-12. Epub 2014 Sep 19.

Immunoterapia Oncologica, Dipartimento di Oncologia Medica, Istituto Toscano Tumori, Azienda Ospedaliera Universitaria Senese, Viale Mario Bracci n. 16, 53100, Siena, Italy,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-014-1609-9DOI Listing
January 2015

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

N Engl J Med 2014 Nov 29;371(20):1867-76. Epub 2014 Sep 29.

From Royal Marsden Hospital, London (J.L.); Istituto Nazionale Tumori Fondazione G. Pascale, Naples (P.A.A.), Azienda Ospedaliera Universitaria Senese, Siena (M. Maio), and Papa Giovanni XXIII Hospital, Bergamo (M. Mandalà) - all in Italy; Hôtel Dieu Place Alexis Ricordeau, Nantes (B.D.), Centre Hospitalier Lyon Sud, Pierre-Bénite (L.T.), and Hôpital Saint André, Bordeaux (C.D.) - all in France; Princess Alexandra Hospital, Woolloongabba, QLD (V.A.), and Peter MacCallum Cancer Centre, Melbourne, VIC (G.A.M.) - both in Australia; National Institute of Oncology, Budapest, Hungary (G.L.); N.N. Blokhin Russian Cancer Research Center, Moscow (L.D.), and Moscow City Oncology Hospital 62, Krasnogorsk (D.S.) - both in Russia; Hospital Universitario Virgen Macarena, Seville, Spain (L.C.-M.); University of Tübingen, Tübingen, Germany (C.G.); Genentech, South San Francisco, CA (M.A.S., I.C., N.C., S.P.H.); and Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, Los Angeles (A.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1408868DOI Listing
November 2014

Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

Cancer Treat Rev 2014 Oct 7;40(9):1056-64. Epub 2014 Jul 7.

Department of Surgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2014.06.012DOI Listing
October 2014

Epigenetic markers of prognosis in melanoma.

Methods Mol Biol 2014 ;1102:481-99

Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-62703-727-3_25DOI Listing
June 2014

Epigenetic drugs as immunomodulators for combination therapies in solid tumors.

Pharmacol Ther 2014 Jun 30;142(3):339-50. Epub 2013 Dec 30.

Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2013.12.015DOI Listing
June 2014

Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology.

J Invest Dermatol 2014 May 22;134(5):1389-1396. Epub 2013 Nov 22.

Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA; Research Branch, Sidra Medical and Research Centre, Doha, Qatar. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2013.495DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3989423PMC
May 2014

Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.

Clin Cancer Res 2014 Mar 9;20(6):1601-9. Epub 2013 Dec 9.

Authors' Affiliations: Department of Dermatology, University Medical Center; Department of Internal Medicine II, Section for Transplantation Immunology and Immunohematology, University of Tübingen, Tübingen; German Cancer Research Center (DKFZ); German Cancer Consortium (DKTK), Heidelberg; Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen, Germany; Department of Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Italy; and Skin Cancer Research Group, School of Public Health, Tropical Medicine and Rehabilitation Sciences, James Cook University, Townsville, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2508DOI Listing
March 2014

Biomarkers for immune checkpoint inhibitors--authors' reply.

Lancet Oncol 2014 Jan;15(1):e1-2

Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, 53100 Siena, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70573-4DOI Listing
January 2014

Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?

Oncoimmunology 2014 Jan 3;3(1):e27482. Epub 2014 Jan 3.

Medical Oncology and Immunotherapy; University Hospital of Siena; Istituto Toscano Tumori; Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.27482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984267PMC
January 2014

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

Lancet Oncol 2013 Oct 11;14(11):1104-1111. Epub 2013 Sep 11.

Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70381-4DOI Listing
October 2013

Epigenetics of melanoma: implications for immune-based therapies.

Immunotherapy 2013 Oct;5(10):1103-16

Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt.13.108
Publisher Site
http://dx.doi.org/10.2217/imt.13.108DOI Listing
October 2013

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.

J Transl Med 2013 Aug 29;11:202. Epub 2013 Aug 29.

Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Traversa La Crucca 3, Baldinca Li Punti 07100, Sassari, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-5876-11-202DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765741PMC
August 2013

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

Cancer Immunol Immunother 2013 Jun 17;62(6):1021-8. Epub 2013 Apr 17.

Division of Medical Oncology and Immunotherapy, Department of Oncology, Istituto Toscano Tumori, University Hospital of Siena, Strada delle Scotte 14, 53100 Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-013-1418-6DOI Listing
June 2013

Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.

Cancer Immunol Immunother 2013 Mar 9;62(3):605-14. Epub 2012 Nov 9.

Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Aviano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-012-1365-7DOI Listing
March 2013

Update on the role of ipilimumab in melanoma and first data on new combination therapies.

Curr Opin Oncol 2013 Mar;25(2):166-72

Medical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria Senese, Istituto Toscano Tumori, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32835dae4fDOI Listing
March 2013

The cost of unresectable stage III or stage IV melanoma in Italy.

J Exp Clin Cancer Res 2012 Nov 1;31:91. Epub 2012 Nov 1.

Medical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria Senese, Istituto Toscano Tumori, Strada delle Scotte, 53100, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1756-9966-31-91DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542007PMC
November 2012

Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.

Ann N Y Acad Sci 2012 Oct;1270:8-12

Department of Oncology, Division of Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1749-6632.2012.06757.xDOI Listing
October 2012